The Company made the announcement at the 69th annual Meeting of the American College of Gastroenterology, which focuses on the latest scientific advances in gastrointestinal research, treatment of digestive diseases and clinical practice management.
"The Enteryx Procedure offers patients a GERD treatment option that can provide symptom relief," said Dr. Pruitt. "Patients who respond to PPI treatments - but who are seeking alternatives - may consider discussing the Enteryx Procedure with their physicians as an option to daily PPI medications for symptom management."
To date, 81 patients have been enrolled in the multi-center, prospective study. Treatment satisfaction and GERD symptoms were assessed at baseline, one-month, three-month and six-month post-procedure.
"The data adds to the growing body of evidence supporting the value of the Enteryx Procedure for patients with GERD symptoms," said Michael Phalen, President of the Endoscopy business at Boston Scientific. "More than 2,500 Enteryx Procedures have been performed worldwide, and we are encouraged by the continued clinical success of this alternative for patients suffering from the symptoms of this condition."
In April 2003, the U.S. Food and Drug Administration approved the Enteryx Procedure kit for the treatment of symptoms of GERD in patients responding to and requiring daily pharmacological therapy with PPI medications.
Boston Scientific is a worldwide developer, manufacturer and marketer of medical devices whose products are used in a broad range of interventional medical specialties. For more information, please visit: www.bostonscientific.com.
This press release contains forward-looking statements. The Company wishes to caution the reader of this press release that actual results may differ from those discussed in the forward-looking statements and may be adversely affected by, among other things, risks associated with clinical trials, the regulatory approval process, commercialization of new technologies, third party intellectual property and other factors described in the Company's filings with the Securities and Exchange Commission.